Roche Holding Ltd ADR (RHHBY)

41.57
-0.36(-0.86%)
After Hours
41.57
0.00(0.00%)
- Delayed Data
  • Volume:
    1,010,840
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    41.37 - 41.72

RHHBY Overview

Prev. Close
41.93
Day's Range
41.37 - 41.72
Revenue
65.56B
Open
41.71
52 wk Range
39.17 - 48.72
EPS
2
Volume
1,010,840
Market Cap
298.04B
Dividend (Yield)
1.22 (2.91%)
Average Vol. (3m)
1,893,921
P/E Ratio
21.72
Beta
0.52
1-Year Change
5.48%
Shares Outstanding
855,756,455
Next Earnings Date
Apr 21, 2021
What is your sentiment on Roche Holding Ltd ADR?
or
Market is currently closed. Voting is open during market hours.

Roche Holding Ltd ADR News

Roche Holding Ltd ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuySell
SummaryStrong BuyStrong BuyStrong BuyNeutralNeutral

Roche Holding Ltd ADR Company Profile

Roche Holding Ltd ADR Company Profile

Industry
Major Drugs
Employees
94442

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Read More
  • it will go up: the chart formed an "bulllish doji star"
    0
    • This Is one and only real competitor in covid test from POLAND http://scopefluidics.com/scope-fluidics-is-developing-an-ultra-fast-covid-19-panel-for-its-pcrone-rapid-molecular-diagnostic-system/
      0
      • Roche just announced as the test pushed through for Covid 19 Tessting. Up Up Up!
        1
        • Jan 26, 2020 Sun $41.20 its GENE is dazzling as always focusing on breakthrough sciences
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.